{"SPADE_UN_11331": {"Clinical Information": [{"Medical use": "Necrotizing soft tissue infections", "Company": "Atox Bio Ltd.", "Stage of Development": "Phase III", "Comments": "No more comments", "Clinical Trials": ["NCT01417780", "NCT02469857"]}], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_11331", "Peptide Name": "p2TA(AB103, Reltecimod)", "Sequence": "ASPMLVAYDA", "Source": "Reltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).", "Target Organism": "No MICs found on DRAMP database", "Reference": ["Resolution of organ dysfunction as a predictor of long-term survival in necrotizing soft tissue infections: Analysis of the AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections trial and a retrospective claims database-linked chart study.(PMID:33797490)"], "Biological Activity": ["Antibacterial"], "Frequent Amino Acids": "ADL", "Absent Amino Acids": "CEFGHIKNOQRTUW", "Basic Residues": 0, "Acidic Residues": 1, "Hydrophobic Residues": 8, "Polar Residues": 6, "Positive Residues": 0, "Negative Residues": 1, "Mass": 1037.19, "PI": 4.05, "Net Charge": -1, "Hydrophobicity": 0.81, "Similar Sequences": [{"SPADE_ID": "SPADE_N_14750", "Similarity": 1.0, "Sequence": "GLFDVIKKVASVIGLASP"}, {"SPADE_ID": "SPADE_UN_00081", "Similarity": 1.0, "Sequence": "GLFDIIKKVASVVGLASP"}, {"SPADE_ID": "SPADE_UN_00086", "Similarity": 1.0, "Sequence": "GLFDVIKKVASVIGLASP"}]}}}